News and blogs

Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder ​

Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder RADNOR, Pa.–(BUSINESS WIRE)– Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the launch of an expanded access program (EAP) that will allow the company to offer ganaxolone to patients…

MAIN LESSONS FROM THE 2020 CDKL5 FORUM

2020 is the year when the world discovered the urgency that the rare disease community feels to develop effective medications and cures. It is also the year that prevented us from hosting large conferences, so the 6th edition of the CDKL5 Forum, which would have taken place in London, UK, instead took place October 12-14…